Equities

Exact Sciences Corp

Exact Sciences Corp

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (USD)92.64
  • Today's Change0.83 / 0.90%
  • Shares traded1.74m
  • 1 Year change93.81%
  • Beta1.8217
Data delayed at least 15 minutes, as of Apr 18 2019 20:03 BST.
More ▼

Profile data is unavailable for this security.

About the company

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

  • Revenue in USD (TTM)454.46m
  • Net income in USD-175.15m
  • Incorporated1995
  • Employees1.98k
  • Location
    Exact Sciences Corp441 Charmany DrMADISON 53719-1234United StatesUSA
  • Phone+1 (608) 284-5700
  • Fax+1 (608) 284-5701
  • Websitehttp://www.exactsciences.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EXAS:NAQ since
announced
Transaction
value
Biomatrica IncDeal completed18 Oct 201818 Oct 2018Deal completed40.26%--
Data delayed at least 15 minutes, as of Apr 18 2019 20:03 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Moderna Inc135.07m-401.86m7.73bn760.00--5.05--57.24-1.22-1.220.4094.65------177,721.00-------------284.84------0.0214---34.38---48.92------
SAGE Therapeutics Inc90.27m-372.88m8.19bn637.00--8.77--90.72-8.06-8.061.9618.400.1218----141,715.90-50.30-53.66-55.46-58.90-----413.06-1,030.54----0.00-------38.04--294.32--
Sarepta Therapeutics Inc301.03m-361.92m8.75bn499.00--8.17--29.06-5.42-5.424.5414.520.20410.32717.67603,274.60-24.54-31.69-26.93-35.7188.64---120.23-219.407.49-18.100.2895--94.7484.14-614.01--76.33--
Alnylam Pharmaceuticals, Inc.74.91m-762.30m9.04bn1.07k--6.60--120.62-7.57-7.570.744712.870.042--2.8470,336.15-42.71-34.42-46.97-37.4928.43---1,017.64-762.016.56--0.0225---16.699.69-55.29--99.59--
Ionis Pharmaceuticals Inc599.68m273.74m10.06bn737.0037.239.5644.2116.771.951.954.457.600.300636.6215.84813,670.3010.772.1013.262.5243.3227.7535.856.247.85-4.310.35270.0016.6332.42154.30--54.38--
Seattle Genetics, Inc.654.70m-222.69m11.40bn1.30k--8.91--17.41-1.44-1.444.127.950.54991.565.67502,841.80-18.70-16.85-22.39-20.5986.5188.47-34.01-31.442.67--0.00--35.7619.45-77.40---0.8587--
Elanco Animal Health Inc3.07bn86.50m11.40bn5.59k131.392.1929.813.720.23730.23738.4614.210.34271.525.03548,622.600.9666--1.06--48.6849.852.82-2.541.5514.940.3223--6.159.72125.16-14.65----
EXACT Sciences Corporation454.46m-175.15m11.55bn1.98k--16.61--25.41-1.43-1.433.725.530.42823.6212.86229,874.60-16.50-33.75-18.26-36.9474.0468.50-38.54-97.508.70-10.230.5029--70.86155.8726.81--76.69--
Cardinal Health Inc141.94bn-40.00m13.37bn50.20k--2.2113.760.0942-0.0861-0.0805461.2020.283.4110.7418.202,827,391.00-0.09122.73-0.20896.294.965.35-0.02680.76710.50605.930.599658.285.266.24-149.61--14.5112.53
Mylan NV11.43bn338.00m13.79bn35.00k40.851.136.201.210.65430.682422.1423.590.33362.683.79326,682.800.98632.581.173.1739.9943.622.966.640.82563.050.53180.00-3.9810.60-59.01-11.5324.77--
BioMarin Pharmaceutical Inc.1.49bn-81.81m14.69bn2.85k--4.951,058.059.85-0.4637-0.43758.4216.650.32920.62644.94523,415.90-1.81-5.98-2.12-6.8478.8681.28-5.49-19.562.92-25.900.2186--13.5222.14-3.30--17.28--
AmerisourceBergen Corp.172.87bn1.13bn15.26bn21.00k13.995.009.410.08835.175.46790.7114.454.5714.1214.988,231,703.002.872.0011.168.552.752.730.6270.40630.53417.630.596247.299.6613.81186.9316.2110.6912.59
Data as of Apr 18 2019. Currency figures normalised to Exact Sciences Corp's reporting currency: US Dollar USD

Institutional shareholders

40.48%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 201810.72m8.53%
T. Rowe Price Associates, Inc.as of 31 Dec 20189.86m7.84%
Wellington Management Co. LLPas of 31 Dec 20185.78m4.60%
BlackRock Fund Advisorsas of 31 Dec 20184.80m3.82%
Viking Global Investors LPas of 31 Dec 20183.96m3.15%
Fidelity Management & Research Co.as of 31 Dec 20183.55m2.82%
Columbia Management Investment Advisers LLCas of 31 Dec 20183.32m2.64%
PRIMECAP Management Co.as of 31 Dec 20183.20m2.54%
OppenheimerFunds, Inc.as of 31 Dec 20182.87m2.28%
William Blair Investment Management LLCas of 31 Dec 20182.86m2.27%
More ▼
Data from 31 Dec 2018 - 31 Dec 2018Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.